Diane Gonzales, MD
Psychiatry · Opelousas, LANPI 1992848774
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 25.4% of the total. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $13.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Sunovion Pharmaceuticals Inc.$776
- Alkermes, Inc.$697
- AbbVie$593
- Johnson & Johnson$461
- Teva Pharmaceuticals USA, Inc.$415
- plus $1K from 10 others
What the payments were for
- Food & beverage$5,596100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 94 | $1,419 |
| Sunovion Pharmaceuticals Inc. | 87 | $776 |
| Alkermes, Inc. | 47 | $697 |
| AbbVie(2 entities) | 45 | $593 |
| Johnson & Johnson | 30 | $461 |
| Teva Pharmaceuticals USA, Inc. | 29 | $415 |
| Vanda Pharmaceuticals Inc. | 16 | $307 |
| Otsuka America Pharmaceutical, Inc. | 19 | $303 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $255 |
| Axsome Therapeutics, Inc. | 8 | $139 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Indivior Inc. | 3 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$5,596 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 95 | $788,959 |
| Invega SustennaPaliperidone Palmitate | 127 | $402,617 |
| Invega TrinzaPaliperidone Palmitate | 12 | $99,026 |
| AustedoDeutetrabenazine | 11 | $81,459 |
| VraylarCariprazine Hcl | 42 | $66,055 |
| AuvelityDextromethorphan Hbr/Bupropion | 36 | $42,597 |
| TrintellixVortioxetine Hydrobromide | 51 | $26,629 |
| RexultiBrexpiprazole | 14 | $26,082 |
| UzedyRisperidone | 13 | $25,448 |
| AristadaAripiprazole Lauroxil | 13 | $20,483 |
| Paliperidone ErPaliperidone | 38 | $13,865 |
| Lurasidone Hcl | 66 | $13,283 |
| Aripiprazole | 169 | $9,576 |
| Ziprasidone Hcl | 39 | $4,369 |
| Buspirone Hcl | 330 | $4,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,419 | $788,95995 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $461 | $501,644139 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy, Loxapine | $415 | $108,35361 claims |
| AbbVieVraylar | $593 | $66,05542 claims |
| Axsome Therapeutics, Inc.Auvelity | $139 | $42,59736 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $26,62951 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $303 | $26,08214 claims |
| Alkermes, Inc.Aristada | $697 | $20,48313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Opelousas
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
- Andrew MorsonNew Orleans$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.